Xbrane Biopharma (XBRANE.ST) Stock Price

Xbrane Biopharma Price

OMX·CLOSED
10.10SEK+0.00 (+0.00 %)
Market closed

Revenue has compounded at 47.3% per year over the past 13 years to 152.35 M SEK. Xbrane Biopharma's net margin stands at 83.5%, up from -1,656.2% several years earlier. Analysts set a median price target of 11.22 SEK, implying 11.1% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 79% above its 52-week low.

Xbrane Biopharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Xbrane Biopharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Xbrane Biopharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Xbrane Biopharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Xbrane Biopharma Stock Price History
DateXbrane Biopharma Price
8/6/202610.10 SEK
8/5/202610.10 SEK
8/4/202610.15 SEK
7/31/202610.15 SEK
7/30/202610.20 SEK
7/29/202610.00 SEK
7/28/202610.45 SEK
7/27/202610.55 SEK
7/24/202610.25 SEK
7/23/202610.00 SEK
7/22/202610.00 SEK
7/21/20269.82 SEK
7/20/202610.75 SEK
7/17/202610.90 SEK
7/15/202610.65 SEK
7/14/202610.70 SEK
7/13/202610.90 SEK
7/10/202610.80 SEK
7/9/202610.70 SEK
7/8/202610.95 SEK
7/7/202610.65 SEK
7/6/202610.50 SEK
7/3/202610.80 SEK
7/2/202610.75 SEK
7/1/202610.45 SEK
6/30/202610.60 SEK
6/29/202610.75 SEK
6/26/202610.70 SEK
6/25/202610.90 SEK
6/24/202610.40 SEK
6/23/202610.80 SEK
6/22/202610.70 SEK
6/18/202610.30 SEK
6/17/202610.20 SEK
6/16/202610.00 SEK
6/15/202610.70 SEK
6/12/202610.70 SEK
6/11/202610.45 SEK
6/10/202610.40 SEK
6/9/202610.75 SEK
6/8/202610.30 SEK
6/5/202610.70 SEK
6/4/202610.60 SEK
6/3/20269.90 SEK
6/2/20269.98 SEK
6/1/202610.00 SEK
5/29/202610.45 SEK
5/28/202611.15 SEK
5/27/202611.00 SEK
5/26/202611.10 SEK
5/25/202611.60 SEK
5/22/202610.80 SEK
5/21/202611.45 SEK
5/20/202611.65 SEK
5/19/202611.00 SEK
5/18/202611.05 SEK
5/15/202611.10 SEK
5/13/202610.50 SEK
5/12/20269.76 SEK
5/11/20269.88 SEK
5/8/20269.60 SEK
5/7/20269.70 SEK
5/6/20269.26 SEK
5/5/20269.72 SEK
5/4/20269.88 SEK
4/30/202611.00 SEK
4/29/202610.00 SEK
4/28/202610.25 SEK
4/27/20269.98 SEK
4/24/20269.52 SEK
4/23/20269.40 SEK
4/22/20269.90 SEK
4/21/202610.30 SEK
4/20/202610.85 SEK
4/17/202611.50 SEK
4/16/20268.28 SEK
4/15/20268.30 SEK
4/14/20268.40 SEK
4/13/20267.86 SEK
4/10/20267.44 SEK
4/9/20267.30 SEK
4/8/20267.04 SEK
4/7/20266.90 SEK
4/2/20266.99 SEK
4/1/20266.68 SEK
3/31/20266.35 SEK
3/30/20266.02 SEK
3/27/20266.03 SEK
3/26/20266.00 SEK
3/25/20266.09 SEK
3/24/20265.80 SEK
3/23/20266.00 SEK
3/20/20265.95 SEK
3/19/20265.66 SEK
3/18/20265.70 SEK
3/17/20265.66 SEK
3/16/20265.70 SEK
3/13/20266.01 SEK
3/12/20266.09 SEK
3/11/20266.03 SEK
3/10/20266.00 SEK
3/9/20265.90 SEK
3/6/20265.99 SEK
3/5/20265.90 SEK
3/4/20265.78 SEK
3/3/20265.92 SEK
3/2/20266.20 SEK
2/27/20266.35 SEK
2/26/20266.12 SEK
2/25/20266.26 SEK
2/24/20266.50 SEK
2/23/20267.05 SEK
2/20/20268.70 SEK
2/19/202610.00 SEK
2/18/202610.25 SEK
2/17/202610.10 SEK
2/16/202610.49 SEK
2/13/202610.02 SEK
2/12/202610.40 SEK
2/11/202610.18 SEK
2/10/202610.60 SEK
2/9/202610.40 SEK
2/6/202610.19 SEK
2/5/202610.32 SEK
2/4/20269.91 SEK
2/3/202610.50 SEK
2/2/202610.50 SEK
1/30/202610.71 SEK
1/29/202611.20 SEK
1/28/202611.40 SEK
1/27/202611.83 SEK
1/26/202611.61 SEK
1/23/202612.00 SEK
1/22/202611.57 SEK
1/21/202610.61 SEK
1/20/202611.47 SEK
1/19/202611.10 SEK
1/16/202611.47 SEK
1/15/202611.70 SEK
1/14/202612.00 SEK
1/13/202611.71 SEK
1/12/202611.65 SEK
1/9/202612.13 SEK
1/8/202610.83 SEK
1/7/202611.03 SEK
1/5/202610.44 SEK
1/2/202610.37 SEK
12/30/202510.20 SEK
12/29/202510.23 SEK
12/23/202510.88 SEK
12/22/202510.98 SEK
12/19/202510.76 SEK
12/18/202510.80 SEK
12/17/202510.88 SEK
12/16/202511.10 SEK
12/15/202510.87 SEK
12/12/202510.22 SEK
12/11/202510.98 SEK
12/10/202510.64 SEK
12/9/20259.98 SEK
12/8/20259.06 SEK
12/5/20259.41 SEK
12/4/20259.75 SEK
12/3/20259.09 SEK
12/2/20258.90 SEK
12/1/20258.88 SEK
11/28/20259.10 SEK
11/27/20259.23 SEK
11/26/20259.01 SEK
11/25/20259.81 SEK
11/24/20258.75 SEK
11/21/20258.72 SEK
11/20/20258.94 SEK
11/19/20259.48 SEK
11/18/20259.95 SEK
11/17/202510.06 SEK
11/14/202510.11 SEK
11/13/202510.08 SEK
11/12/202510.38 SEK
11/11/20259.82 SEK
11/10/202510.20 SEK
11/7/202510.11 SEK
11/6/202510.01 SEK
11/5/202510.65 SEK
11/4/202510.55 SEK
11/3/202510.80 SEK
10/31/202510.70 SEK
10/30/202510.44 SEK
10/29/202510.53 SEK
10/28/202510.20 SEK
10/27/202510.48 SEK
10/24/202511.20 SEK
10/23/202515.25 SEK
10/22/202514.99 SEK
10/21/202514.36 SEK
10/20/202515.00 SEK
10/17/202515.00 SEK
10/16/202520.05 SEK
10/15/202520.28 SEK
10/14/202520.89 SEK
10/13/202521.13 SEK
10/10/202521.49 SEK
10/9/202521.34 SEK
10/8/202520.62 SEK
10/7/202520.50 SEK
10/6/202520.30 SEK
10/3/202521.02 SEK
10/2/202521.33 SEK
10/1/202521.71 SEK
9/30/202520.97 SEK
9/29/202520.20 SEK
9/26/202520.39 SEK
9/25/202519.76 SEK
9/24/202521.07 SEK
9/23/202521.12 SEK
9/22/202521.10 SEK
9/19/202521.26 SEK
9/18/202521.18 SEK
9/17/202519.73 SEK
9/16/202519.07 SEK
9/15/202519.81 SEK
9/12/202520.02 SEK
9/11/202519.72 SEK
9/10/202519.72 SEK
9/9/202520.92 SEK
9/8/202521.63 SEK
9/5/202521.15 SEK
9/4/202521.74 SEK
9/3/202522.31 SEK
9/2/202522.56 SEK
9/1/202522.48 SEK
8/29/202523.26 SEK
8/28/202521.76 SEK
8/27/202520.97 SEK
8/26/202520.92 SEK
8/25/202523.42 SEK
8/22/202523.02 SEK
8/21/202523.00 SEK
8/20/202523.03 SEK
8/19/202522.95 SEK
8/18/202523.47 SEK
8/15/202523.10 SEK
8/14/202523.59 SEK
8/13/202523.08 SEK
8/12/202523.43 SEK
8/11/202523.67 SEK
Access this data via the Eulerpool API
Get Free API Key

Xbrane Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
57.62 M SEK
-166.22 M SEK
-172.23 M SEK
Jan 1, 2023
238.73 M SEK
-310.43 M SEK
-388.17 M SEK
Jan 1, 2024
198.70 M SEK
-217.92 M SEK
-266.22 M SEK
Jan 1, 2025
152.35 M SEK
-72.14 M SEK
127.24 M SEK
Jan 1, 2026 (e)
180.00 M SEK
-151.35 M SEK
-39.97 M SEK
Jan 1, 2027 (e)
222.00 M SEK
-186.66 M SEK
-206,054.00 SEK
Jan 1, 2028 (e)
319.00 M SEK
-268.22 M SEK
0.00 SEK
Jan 1, 2029 (e)
405.00 M SEK
-340.53 M SEK
0.00 SEK

Xbrane Biopharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 2:33 PM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
––2.0020.00112.00–6.0011.0057.00238.00198.00152.00180.00222.00319.00405.00
–––900.00460.00––83.33418.18317.54-16.81-23.2318.4223.3343.6926.96
––-200.0020.0086.61–33.33718.1871.9314.7190.9151.9751.9751.9751.9751.97
79.0079.00-4.004.0097.00-17.002.0079.0041.0035.00180.0079.0093.55115.38165.80210.49
-2.00-11.00-33.00-44.00-11.00-164.00-225.00-180.00-166.00-310.00-217.00-72.00-151.00-186.00-268.00-340.00
––-1,650.00-220.00-9.82–-3,750.00-1,636.36-291.23-130.25-109.60-47.37-83.89-83.78-84.01-83.95
-2.00-11.00-33.00-44.00-13.00-167.00-226.00-191.00-172.00-388.00-266.00127.00-39.00–––
–450.00200.0033.33-70.451,184.6235.33-15.49-9.95125.58-31.44-147.74-130.71–––
0.170.170.350.420.460.941.421.721.912.1012.24464.97464.97464.97464.97464.97
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Xbrane Biopharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Xbrane Biopharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Xbrane Biopharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Xbrane Biopharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Xbrane Biopharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Xbrane Biopharma stock margins

The Xbrane Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xbrane Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xbrane Biopharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-5.93 %
-1,565.79 %
-1,656.22 %
Jan 1, 2022
71.23 %
-288.48 %
-298.91 %
Jan 1, 2023
14.82 %
-130.03 %
-162.60 %
Jan 1, 2024
90.83 %
-109.67 %
-133.98 %
Jan 1, 2025
52.23 %
-47.35 %
83.52 %
Jan 1, 2026 (e)
52.23 %
-84.08 %
-22.21 %
Jan 1, 2027 (e)
52.23 %
-84.08 %
-0.09 %
Jan 1, 2028 (e)
52.23 %
-84.08 %
0.00 %

Xbrane Biopharma Stock Revenue, EBIT, Earnings per Share

The Xbrane Biopharma earnings per share therefore indicates how much revenue Xbrane Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
6.72 SEK
-105.23 SEK
-111.31 SEK
Jan 1, 2022
30.22 SEK
-87.18 SEK
-90.33 SEK
Jan 1, 2023
113.49 SEK
-147.58 SEK
-184.54 SEK
Jan 1, 2024
16.24 SEK
-17.81 SEK
-21.76 SEK
Jan 1, 2025
0.33 SEK
-0.16 SEK
0.27 SEK
Jan 1, 2026 (e)
8.74 SEK
-0.33 SEK
-1.94 SEK
Jan 1, 2027 (e)
10.77 SEK
-0.40 SEK
-0.01 SEK
Jan 1, 2028 (e)
15.48 SEK
-0.58 SEK
0.00 SEK

Xbrane Biopharma business model & stock analysis

Xbrane Biopharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Xbrane Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

Xbrane Biopharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Xbrane Biopharma shares outstanding

The number of shares of Xbrane Biopharma was 464.97 M in 2025. This indicates how many shares Xbrane Biopharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
1.72 M Stocks
Jan 1, 2022
1.91 M Stocks
Jan 1, 2023
2.10 M Stocks
Jan 1, 2024
12.24 M Stocks
Jan 1, 2025
464.97 M Stocks
Jan 1, 2026 (e)
464.97 M Stocks
Jan 1, 2027 (e)
464.97 M Stocks
Jan 1, 2028 (e)
464.97 M Stocks

Xbrane Biopharma stock splits

In Xbrane Biopharma's history, there have been no stock splits.

Current Xbrane Biopharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
82.40 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
11.22
Last Price
10.10
Currency
SEK
12M Return Potential
11.09 %
LTM Return
0 %

Xbrane Biopharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/15/2024-3.34SEK-62.12 MSEK-2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Xbrane Biopharma stock

58/100
50
Environment
45
Social
79
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy10
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions10
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees61
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Xbrane Biopharma shareholder structure

% Name
12.10165%
Pouya (Ashkan)
Pouya (Ashkan)
11.41934%
Six Rays Pte. Ltd.
Six Rays Pte. Ltd.
5.98279%
Westman (Bengt Goran)
Westman (Bengt Goran)
3.60937%
Stodberg (Hakan)
Stodberg (Hakan)
3.22194%
Avanza Bank Holding AB
Avanza Bank Holding AB
2.25895%
Nordnet Pensionsforsakring AB
Nordnet Pensionsforsakring AB

Xbrane Biopharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
67.8%
Float Shares
-
Shares Outstanding
-

Xbrane Biopharma Executives and Management Board

11 members · avg. age 52 · 36 % women

MA

Mr. Martin Amark (45)

Chief Executive Officer

3.37 M SEK

Management

SB

Mr. Siavash Bashiri (42)

Deputy Chief Executive Officer, Head - Biosimilars

1.76 M SEK
DV

Dr. David Vikstroem (48)

Chief Technology Officer

449,008.00 SEK
JB

Ms. Jane Benyami (46)

Acting Chief Financial Officer

–
DJ

Ms. Dina Jurman (43)

Head - Clinical Affairs

–
AW

Mr. Anders Wallstroem (49)

Head - Manufacturing and Supply Chain

–

Board of Directors

AT

Mr. Anders Tullgren (64)

Independent Chairman of the Board

773,000.00 SEK
EN

Ms. Eva Nilsagard (61)

Independent Director

471,000.00 SEK
MT

Mr. Mats Thoren (54)

Independent Director

412,000.00 SEK
KG

Ms. Kirsti Gjellan (62)

Independent Director

378,000.00 SEK
KB

Mr. Kristoffer Bissessar (57)

Independent Director

299,000.00 SEK

Xbrane Biopharma Supply Chain

Xbrane Biopharma Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Syneos Health A
Supplier·Life Sciences Tools & Services·US
0.40
0.88
0.70
0.63
0.17
0.71
2
Bausch Health
Supplier·Customer·CA
0.66
0.86
0.56
0.53
0.80
0.68
3
Swedbank A
Supplier·Customer·SE
0.11
-0.57
0.05
0.36
-0.08
0.46

Frequently asked questions about Xbrane Biopharma

Analysts currently set an average price target of 11.22 SEK for the Xbrane Biopharma stock (median: 11.22 SEK), implying +11.1 % versus the latest price. The consensus is based on 5 analyst ratings.

Xbrane Biopharma Analyst Price Targets 2026

6 analysts currently rate the Xbrane Biopharma stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Xbrane Biopharma to generate revenue of 180.00 M SEK and earnings per share of -0.09 SEK.

Xbrane Biopharma Analyst Price Targets 2026

Converted at the current exchange rate, the Xbrane Biopharma share trades at 0.92 EUR (10.10 SEK).

The Xbrane Biopharma share (XBRANE.ST) is listed on 4 stock exchanges, including: Frankfurt (7XB.F), München (7XB.MU).

No history available for Xbrane Biopharma.

The expected revenue of Xbrane Biopharma is 180.00 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Xbrane Biopharma is -39.97 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Xbrane Biopharma is currently -117.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Xbrane Biopharma stock.

The price-to-sales ratio (P/S) of Xbrane Biopharma is currently 26.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Xbrane Biopharma stock.

The Eulerpool Quality Score for Xbrane Biopharma is 4/10.

The ISIN of Xbrane Biopharma is SE0026598583. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Xbrane Biopharma is A2ADY1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Xbrane Biopharma is XBRANE.ST. The ticker symbol is used to trade Xbrane Biopharma shares on the stock exchange.

Xbrane Biopharma paid dividends every year for the past 0 years.

Xbrane Biopharma is assigned to the 'Health' sector.

The dividends of Xbrane Biopharma are distributed in SEK.

All fundamentals and in-depth analysis of Xbrane Biopharma

Our stock analysis for Xbrane Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xbrane Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Xbrane Biopharma Stock
Xbrane Biopharma Revenue→
Xbrane Biopharma Stock
Xbrane Biopharma Net Income→
Xbrane Biopharma Stock
Xbrane Biopharma P/E→
Xbrane Biopharma Stock
Xbrane Biopharma P/S→
Xbrane Biopharma Stock
Xbrane Biopharma EBIT→
Xbrane Biopharma Stock
Xbrane Biopharma Dividend→
Xbrane Biopharma Stock
Xbrane Biopharma Directors Dealings→
Xbrane Biopharma Stock
Xbrane Biopharma Stocks→
Xbrane Biopharma Stock
Xbrane Biopharma Market capitalization→
Xbrane Biopharma Stock
Xbrane Biopharma Debt→
Xbrane Biopharma Stock
Xbrane Biopharma Liabilities→
Xbrane Biopharma Stock
Xbrane Biopharma Equity→
Xbrane Biopharma Stock
Xbrane Biopharma AAQS→
Xbrane Biopharma Stock
Xbrane Biopharma Employees→
Xbrane Biopharma Stock
Xbrane Biopharma ROE→
Xbrane Biopharma Stock
Xbrane Biopharma ROA→
Xbrane Biopharma Stock
Xbrane Biopharma ROCE→
Xbrane Biopharma Stock
Xbrane Biopharma News→
Xbrane Biopharma Stock
Xbrane Biopharma Analyst Price Targets→

Health Stocks

XcelerateXBiotechXCell TherapeuticsX4 PharmaceuticalsXcorporealWuXi XDC CaymanXencorWuXi Biologics (Cayman)Xenetic BiosciencesWuXi AppTec CoXeno AeronauticsWuhan YZY Biopharma CoAll Stocks A–Z →